the staff of the Ridgewood blog
Washington DC, On Monday, the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health announced that a Phase 1 clinical trial evaluating an investigational vaccine designed to protect against COVID-19 has begun at Kaiser Permanente Washington Health Research Institute in Seattle, funded by NIH.